A case report of a psoriatic arthritis patient on hemodialysis treated with tumor necrosis factor blocking agent and a literature review
| dc.contributor.author | Saougou, I. | en |
| dc.contributor.author | Papagoras, C. | en |
| dc.contributor.author | Markatseli, T. E. | en |
| dc.contributor.author | Voulgari, P. V. | en |
| dc.contributor.author | Drosos, A. A. | en |
| dc.date.accessioned | 2015-11-24T19:40:40Z | |
| dc.date.available | 2015-11-24T19:40:40Z | |
| dc.identifier.issn | 1434-9949 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/24388 | |
| dc.rights | Default Licence | - |
| dc.subject | Antibodies, Monoclonal/pharmacology/*therapeutic use | en |
| dc.subject | Arthritis, Psoriatic/complications/*drug therapy | en |
| dc.subject | Humans | en |
| dc.subject | Kidney Failure, Chronic/*complications/therapy | en |
| dc.subject | Male | en |
| dc.subject | Middle Aged | en |
| dc.subject | Renal Dialysis | en |
| dc.subject | Tumor Necrosis Factor-alpha/*antagonists & inhibitors | en |
| dc.title | A case report of a psoriatic arthritis patient on hemodialysis treated with tumor necrosis factor blocking agent and a literature review | en |
| heal.abstract | This report seeks to describe the clinical efficacy and safety of infliximab in a patient with psoriatic arthritis on hemodialysis and to review the literature on the topic. We present a patient with psoriatic arthritis on hemodialysis treated with infliximab and we review the literature. Our case includes a patient with severe psoriasis and dactylitis with chronic renal failure requiring regular hemodialysis. At presentation the patient had a psoriasis area and severity index (PASI) score of 35.1 and dactylitis affecting the right thumb. Evaluation of laboratory parameters revealed a slight increase of erythrocyte sedimentation rate (21 mm/h) and a mild normocytic anemia (Hct 36.4). The rest of the laboratory and imaging tests were within normal limits. Infliximab was initiated at the loading dose of 5 mg/kg body weight at weeks 0, 2, 6, and every 8 weeks thereafter. On retreatment at week 14 the PASI score was measured to 3.4. After the conclusion of 6 months of treatment, the reduction of PASI score was sustained reaching the point of 0.8. In addition, dactylitis, as well as laboratory parameters, showed a striking improvement. On the other hand, during the same period of time, no changes of renal functions were noted and no complications were reported and the patient continued his hemodialysis on a regular basis. Our case is in accordance with other reports supporting that infliximab treatment in patients undergoing hemodialysis can be safe, well tolerated, and effective. However, larger trials are needed to prove its use in these patients. | en |
| heal.access | campus | - |
| heal.fullTextAvailability | TRUE | - |
| heal.identifier.primary | 10.1007/s10067-010-1485-4 | - |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/20490588 | - |
| heal.identifier.secondary | http://www.springerlink.com/content/k7477612m01501h4/fulltext.pdf | - |
| heal.journalName | Clin Rheumatol | en |
| heal.journalType | peer-reviewed | - |
| heal.language | en | - |
| heal.publicationDate | 2010 | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.type | journalArticle | - |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.type.en | Journal article | en |
Αρχεία
Φάκελος/Πακέτο αδειών
1 - 1 of 1
Φόρτωση...
- Ονομα:
- license.txt
- Μέγεθος:
- 1.74 KB
- Μορφότυπο:
- Item-specific license agreed upon to submission
- Περιγραφή: